List view / Grid view
An effective quality risk management (QRM) process provides a key mechanism for the proactive identification and control of potential issues that may arise during product development and subsequent commercialisation1. In this context, risk is defined as the combination of the probability of occurrence of harm (or unwanted outcome) and the…
9 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza®...
2 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients...
2 April 2014 | By GlaxoSmithKline
Data from the first patient preference study in advanced renal cell carcinoma are published in the Journal of Clinical Oncology...
31 March 2014 | By GlaxoSmithKline
GSK announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth...
27 March 2014 | By GlaxoSmithKline
Novel scientific collaboration to use genomics and big data to drive drug discovery...
26 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide)...
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies...
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment...
12 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reduction in the frequency of exacerbations...
10 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that GSK has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India (GlaxoSmithKline Pharmaceuticals Limited), from 50.7% to 75%...
28 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Promacta™...
21 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium under the proposed brand name Incruse®...
20 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol under the proposed brand name Anoro®...
